BerGenBio

Legal Proceedings Report • Sep 13, 2018

BerGenBio ASA: Notice of Arbitration with Rigel Pharmaceuticals, Inc.

BerGenBio ASA: Notice of Arbitration with Rigel Pharmaceuticals, Inc.

Bergen, Norway, 13 September 2018 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, today served Notice of Arbitration to Rigel Pharmaceuticals, Inc. pursuant to a License Agreement made and entered into as of 29 June 2011.

A dispute has arisen between the Parties with respect to the interpretation and application of certain provisions of the Agreement, particularly as they relate to the rights and obligations of the parties in the event of the licensing or sale of a Product(s) by BerGenBio and/or the sale of BerGenBio to a third party.

The Parties agreed to a binding arbitration before a panel of three (3) arbitrators in Toronto, Canada pursuant to the then-current Canadian Arbitration Association rules, to be completed with 180 days of commencement.

- Ends -

About BerGenBio ASA

BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors as a potential cornerstone of combination cancer therapy. The Company is a world leader in understanding the essential role of AXL kinase in mediating cancer spread, immune evasion and drug resistance in multiple aggressive solid and haematological cancers.

BerGenBio's lead product, bemcentinib (BGB324), is a selective, potent and orally bio- available small molecule AXL inhibitor in four Company sponsored Phase II clinical trials in major cancer indications.

Contact

Richard Godfrey, CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

Media Relations

Jan Petter Stiff, Crux Adviser

stiff@crux.no

+47 995 13 891

David Dible, Mark Swallow, Marine Perrier: Citigate Dewe Rogerson bergenbio@citigatedewerogerson.com

+44 207 638 9571

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.